In addition, when IPF patients were classified into stable or progressors according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines (10), patients with a progressive disease had higher FAPα levels than controls and stable patients (Figure 2) (51). The gene discussed is FAP; the disease is idiopathic pulmonary fibrosis.